<!DOCTYPE html>
<html lang="en-GB">
    <head>
        <meta charset="utf-8" /> 
        <meta content="IE=edge,chrome=1" name="X-UA-Compatible" />
        <meta content="width=device-width, initial-scale=1, maximum-scale=1" name="viewport" />
        <!-- Timestamp: 03/10/2015 20:27:53 609487-WEB09-->
        <title>BNF | ATROPINE SULFATE</title>
        
        <script src="//cdn.optimizely.com/js/2225620398.js"></script> 
        <link href="//fonts.googleapis.com/css?family=Lato:200normal,200italic,300normal,300italic,400normal,400italic,700normal,700italic,900normal,900italic" rel="stylesheet" type="text/css" />
<link href="//cdn.nice.org.uk/v3/content/NICE.bootstrap.css" rel="stylesheet" type="text/css" />
<link href="//www.nice.org.uk/Themes/NICE.Bootstrap/styles/nice/NICE.base.less" rel="stylesheet" type="text/css" />
<link href="//cdn.nice.org.uk/v2/Content/FontAwesome.css" rel="stylesheet" type="text/css" />
<link href="//cdn.nice.org.uk/v2/Content/NICE.glyphs.css" rel="stylesheet" type="text/css" />

<script src="//ajax.aspnetcdn.com/ajax/jQuery/jquery-1.11.1.min.js" type="text/javascript"></script>
<script src="//www.nice.org.uk/Themes/NICE.Bootstrap/scripts/JSON/JSON2.js" type="text/javascript"></script>
<script src="//www.nice.org.uk/Themes/NICE.Bootstrap/scripts/niceorg/NICE.GA.js" type="text/javascript"></script>

        <meta content="3963" name="cid" />


 
  <meta content="NICE" name="DC.Publisher" />
  <meta content="All content on this site is NICE copyright unless otherwise stated. You can download material for private research, study or in-house use only. Do not distribute or publish any material from this site without first obtaining NICE's permission. Where Crown copyright applies, see the Office of Public Sector Information (formerly HMSO) website for information." name="DC.Rights.Copyright" />
  <meta content="eng" name="DC.Language" scheme="DCTERMS.ISO639-2T" />
  <meta content="Health, well-being and care" name="DC.Subject" scheme="eGMS.IPSV" />
  <meta content="Double-A" name="eGMS.accessibility" scheme="eGMS.WCAG10" />
  <meta content="2014-08-05" name="DC.Issued" scheme="DCTERMS.W3CDTF" />
  <meta content="2014-08-05" name="DC.Modified" scheme="DCTERMS.W3CDTF" />
  <meta content="CorporatePage" name="DC.Type" scheme="NICE.Publication.Types" />
  
        
        <meta content="Local government | NICE communities | About | NICE" name="DC.Title" />
        <meta content="#f6f6f6" name="msapplication-TileColor" />
        <meta content="//cdn.nice.org.uk/V3/Content/nice/favicon-144.png" name="msapplication-TileImage" />
        <link rel="shortcut icon" href="//cdn.nice.org.uk/V3/Content/nice/favicon.ico" />
        <link rel="apple-touch-icon-precomposed" href="//cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
            <link rel="canonical" href="https://www.nice.org.uk/about/nice-communities/local-government" />
        <!--[if IE 6]><script>var ieVersion = 6;</script><![endif]-->
        <!--[if IE 7]><script>var ieVersion = 7;</script><![endif]-->
        <!--[if IE 8]><script>var ieVersion = 8;</script><![endif]-->
        <!-- addthis config -->
        <script>
            var addthis_config = {
                data_ga_property: 'UA-28620212-1',
                data_ga_social: true,
                ui_show_promo: false,
                services_compact: '',
                pubid: 'ra-5506be4a13ce4bf0'
            };
            $(function () {
                addthis.init();
            });
        </script>
        
<script>
jQuery.fn.topLink = function(settings) {
  settings = jQuery.extend({
    min: 1,
    fadeSpeed: 100
  }, settings);
  return this.each(function() {
    //listen for scroll
    var el = jQuery(this);
    el.hide(); //in case the user forgot
    jQuery(window).scroll(function() {
      if(jQuery(window).scrollTop() >= settings.min)
      {
        el.fadeIn(settings.fadeSpeed);
      }
      else
      {
        el.fadeOut(settings.fadeSpeed);
      }
    });
  });
};

//usage w/ smoothscroll
jQuery(document).ready(function() {
  //set the link
  jQuery('#top-link').topLink({
    min: 500,
    fadeSpeed: 100
  });
  //smoothscroll
  jQuery('#top-link').click(function(r) {    
    jQuery("html, body").animate({ scrollTop: 0 }, 300);
  });
});
</script>
        
<style>

#two-columns {
 
 width: 100%;
 -moz-column-count: 2;
  -moz-column-gap: 64px;
  -webkit-column-count: 2;
  -webkit-column-gap: 64px;
  column-count: 2;
  column-gap: 64px;
 }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass=title], .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

 h1, h2, h3, h4, h5, h6 {
    margin: 0 0 12px;
    font-family: inherit;
    font-weight: 600;
    line-height: normal;
    color: #4a4a4a;
    text-rendering: optimizelegibility;
}
h1 {
    font-size: 48px;
}
h2 {
    font-size: 36px;
}
h3 {
    font-size: 24px;
}
h4 {
    font-size: 18px;
}
hr {
    margin: 0 0 14px;
    border: 0margin: 24px 0;;
    border-top: 1px solid #DCDCDC;
    border-bottom: 1px solid #fff;
}
p {
    margin: 0 0 12px;
}

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 1rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 10px solid #0288d1;
  }
  .doses .child {
    border-left: 10px solid #82176F;
  }
  .doses .info {
    border-left: 10px solid #468847;
  }
  .lead {
    margin-bottom: 0px; 
    font-size: 20px;
    font-weight: 400;
    line-height: 28px;
}

  
.alert {
    text-shadow: none;
}
.alert-block {
    padding-top: 35px;
    padding-bottom: 35px;
}
.alert, .alert h4 {
    color: #4a4a4a;
}
.alert {
    padding: 25px;
    margin-bottom: 24px;
    margin-top: 24px;
    text-shadow: 0 1px 0 rgba(255,255,255,.5);
    background-color: #fff;
    border: 5px solid #0288d1;
    -webkit-border-radius: 0;
    -moz-border-radius: 0;
    border-radius: 0;

}
.alert-info {
    background-color: #f6fbfd;
    border-color: #d9f2f7;
    color: #3a87ad;
    font-size: 18px;
}
  /* DITA symbols */

  ph {
    color: #006;
  }

  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }
  .tab-pane {
    padding: 0px;
}
  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype=reg]::before {
    content: "\00ae";
  }
  tm[tmtype=copy]::before {
    content: "\00a9";
  }
  tm[tmtype=trade]::before {
    content: "\2122";
  }
#wrap {height:auto; width:auto; margin:0 auto;}
#top-link  {display:none; position:fixed; left:50%; margin-left:78px; bottom:320px; color:#292f33; font-weight:400; text-decoration:none; border:none; background:#c1ccd2; padding:12px 18px; box-shadow: inset 0 -1px 0 0 rgba(0,0,0,.1); opacity:0.8 }

</style>
        <!-- end addthis config -->
        
    </head>


<body data-spy="scroll" data-target=".aside-primary" >
                
<div id='gtmscript'></div>    <!-- Google Tag Manager -->
            <noscript>
                <iframe src="//www.googletagmanager.com/ns.html?id=GTM-M55QTQ"
                        height="0" width="0" style="display:none;visibility:hidden"></iframe>
            </noscript>
            <script>
                (function (w, d, s, l, i) {
                    w[l] = w[l] || []; w[l].push({
                        'gtm.start':
                            new Date().getTime(), event: 'gtm.js'
                    }); var f = d.getElementsByTagName(s)[0],
                            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
                                '//www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
                })(window, document, 'script', 'dataLayer', 'GTM-M55QTQ');</script>
            <!-- End Google Tag Manager -->
        
        
<div id="printpane"></div>
    <div class="nice-tophat">
        <div class="nice-global" id="nice-global">
            <div class="tophat-inner">
                <div class="zone zone-navigation">

<div class="widget-navigation widget-search-widget widget">
    <div class="widget-content">
      
    </div>
  </div>

<div class="widget-navigation widget-menu-widget widget">
    <div class="widget-content">
      <ul class="nav nav-pills menu">
    
    

<li><a href="/news">News</a>
</li>

<li><a href="/about">About</a>
</li>

<li><a href="/get-involved">Get involved</a>
</li>

<li><a href="/about/nice-communities">Communities</a>
</li>
</ul>
    </div>
  </div></div>
            </div>
        </div>
    </div>

<div class="layout ">
    <div class="">
            <div class="zone zone-content">



<div class="page-content corporate-content">
  <div class="metadata">
    
  </div>
  
<div class="row">
<ul class="breadcrumb"> 
<li><a href="#">Home</a><i class="divider icon-nice-chevron-right"></i></li>
<li><a href="#">Drugs</a> <i class="divider icon-nice-chevron-right"></i></li>
<li class="active"><a href="#">Pirfenidone</a></li>
</ul>
</div>

    <div class="row">
<div class="span8">
<h1>ATROPINE SULFATE</h1>
<div class="row">
<div style="height:1em">&nbsp;</div>
<ul class="unstyled" id="two-columns">
          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#breastfeeding" data-toggle="tab">Breast feeding</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra-indications</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#interactions" data-toggle="tab">Interactions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#directionsforadministration" data-toggle="tab">Directions for administration</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#patientandcareradvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#lessSuitableForPrescribing" data-toggle="tab">Less suitable for prescribing</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
          </ul>

<hr>

<div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>
<hr style="margin: 10px 0;">
        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cycloplegia</span>
            </h4>
            <p class="specificity"><span class="route">To the eye using eye drop</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                (consult product literature).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Anterior uveitis</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye using eye drop</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                (consult product literature).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bradycardia due to acute massive overdosage of beta-blockers</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                3 mg.</li>
              <li class="dose child"><strong>For children </strong><br>
                40 micrograms/kg (max. per dose 3 mg).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of poisoning by organophosphorus insecticide or nerve agent (in combination with pralidoxime chloride)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                2 mg every 5–10 minutes until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished, frequency of administration dependent on the severity of poisoning.</li>
              <li class="dose child"><strong>For children </strong><br>
                20 micrograms/kg every 5–10 minutes (max. per dose 2 mg) until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished, frequency of administration dependent on the severity of poisoning.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                0.6–1.2 mg daily, dose to be taken at night.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Premedication</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection or by intramuscular injection</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                300–600 micrograms, to be administered immediately before induction of anaesthesia.</li>
              <li class="dose adult"><strong>For adults </strong><br>
                300–600 micrograms, to be administered 30–60 minutes before induction of anaesthesia.</li>
              <li class="dose child"><strong>For children 12–17 years</strong><br>
                300–600 micrograms, to be administered immediately before induction of anaesthesia.</li>
              <li class="dose child"><strong>For children 12–17 years</strong><br>
                300–600 micrograms, to be administered 30–60 minutes before induction of anaesthesia.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Intra-operative bradycardia</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                300–600 micrograms, larger doses may be used in emergencies.</li>
              <li class="dose child"><strong>For children 12–17 years</strong><br>
                300–600 micrograms, larger doses may be used in emergencies.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Control of muscarinic side-effects of neostigmine in reversal of competitive neuromuscular block</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                0.6–1.2 mg.</li>
              <li class="dose child"><strong>For children 12–17 years</strong><br>
                0.6–1.2 mg.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Excessive bradycardia associated with beta-blocker use</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                0.6–2.4 mg every hour in divided doses (max. per dose 600 micrograms).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bradycardia following myocardial infarction (particularly if complicated by hypotension)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses unstyled">
              <li class="dose adult"><strong>For adults </strong><br>
                500 micrograms every 3–5 minutes; maximum 3 mg.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



<section class="tab-pane" id="pregnancy">
<h2>Pregnancy</h2>
<hr style="margin: 10px 0;">
<section class="generalInformation">
<h4 class="specificity">With systemic use:</h4>
<ul>
<li>Not known to be harmful; manufacturer advises caution.</li>
</ul>
</section>
</section>

<section class="tab-pane" id="breastfeeding">
<h2>Breast feeding</h2>
<hr style="margin: 10px 0;">
<section class="generalInformation">
<h4 class="specificity">With <ph outputclass="route">systemic</ph> use</h4>
<ul>
<li>May suppress lactation; small amount present in milk—manufacturer advises caution.</li>
</ul>
</section>
</section>






<section class="tab-pane" id="sideEffects">
<h2>Side effects</h2>

<h3>For all ANTIMUSCARINICS (SYSTEMIC):</h3>
<hr style="margin: 10px 0;">
<h4>Common or very common</h4>
<hr style="margin: 10px 0;">
<p>Constipation; dilation of pupils with loss of accommodation; dry mouth; photophobia; reduced bronchial secretions; skin dryness; skin flushing; transient bradycardia (followed by tachycardia, palpitation and arrhythmias); urinary retention; urinary urgency</p>

<h4>Uncommon</h4>
<hr style="margin: 10px 0;">
<p>Confusion (particularly in the elderly); giddiness; nausea; vomiting</p>

<h4>Very rare</h4>
<hr style="margin: 10px 0;">
<p>Angle-closure glaucoma</p>

<h4>Frequency not known</h4>
<hr style="margin: 10px 0;">
<p>Angioedema; blurred vision; blurred vision; central nervous system stimulation; convulsion; diarrhoea; difficulty in micturition; disorientation; dizziness; drowsiness; dry eyes; euphoria; fatigue; flatulence; hallucinations; headache; impaired memory; palpitation; photosensitivity; rash; reduced sweating (may lead to heat sensations and fainting in hot environments or patients with fever); restlessness; taste disturbances</p>        

<div style="height:1em">&nbsp;</div> 
<h3>For all ANTIMUSCARINICS (EYE):</h3><hr style="margin: 10px 0;">
<h4>Frequency not known</h4>
<hr style="margin: 10px 0;">
<p>Conjunctivitis (on prolonged administration); contact dermatitis; eye oedema (on prolonged administration); hyperaemia (on prolonged administration); local irritation (on prolonged administration); raised intraocular pressure; transient stinging</p>

<div style="height:1em">&nbsp;</div>
<h3>For ATROPINE SULFATE:</h3>
<hr style="margin: 10px 0;">
<h4>Side-effects, further information</h4> 
<hr style="margin: 10px 0;">
<h4 class="specificity">When used by <ph outputclass="route">eye</ph> in children</h4>
<ul>
<li>Toxic systemic reactions can occur in neonates and children.</li>
</ul>

<h4 class="specificity">When used by <ph outputclass="route">eye</ph></h4>
<ul>
<li>Systemic side-effects can occur, particularly in children and the elderly.</li>
</ul>
      
        
      </section>

<section class="tab-pane" id="directionsForAdministration">
<h2>Directions for administration</h2>
<hr style="margin: 10px 0;">
<section class="directionsForAdministration">
<h4 class="specificity">With <ph outputclass="route">oral</ph> use in children</h4>
<p>For administration <i>by mouth</i>, injection solution may be given orally.</p>
</section>
</section>



<section class="tab-pane" id="importantSafetyInformation">
<h2>Important safety information</h2>
<hr style="margin: 10px 0;">
<div class="alert">
<p class="lead">Antimuscarininc drugs used for premedication to general anaesthesia should only be administered by, or under the direct supervision of, personnel experienced in their use.</p>
</div>
</section>

<section class="tab-pane" id="contraindications">
<h2>Contra-indications</h2>
<h3>For all ANTIMUSCARINICS (SYSTEMIC):</h3>
<hr style="margin: 10px 0;">
<p>Gastro-intestinal obstruction; intestinal atony; myasthenia gravis (but some antimuscarinics may be used to decrease muscarinic side-effects of anticholinesterases); paralytic ileus; prostatic enlargement; pyloric stenosis; severe ulcerative colitis; significant bladder outflow obstruction; toxic megacolon; urinary retention</p>
</section>

<section class="tab-pane" id="cautions">
<h2>Cautions</h2>
<h3>For all ANTIMUSCARINICS (SYSTEMIC):</h3>
<hr style="margin: 10px 0;">
<p>Acute myocardial infarction; arrhythmias (may be worsened); autonomic neuropathy; cardiac insufficiency (due to association with tachycardia); cardiac surgery (due to association with tachycardia); conditions characterised by tachycardia; congestive heart failure (may be worsened); coronary artery disease (may be worsened); diarrhoea; elderly (especially if frail); gastro-oesophageal reflux disease; hiatus hernia with reflux oesophagitis; hypertension; hyperthyroidism (due to association with tachycardia); individuals susceptible to angle-closure glaucoma; prostatic hyperplasia; pyrexia; ulcerative colitis.</p>
<h3>For all ANTIMUSCARINICS (EYE):</h3>
<hr style="margin: 10px 0;">
<p>Darkly pigmented iris is more resistant to pupillary dilatation and caution should be exercised to avoid overdosage; mydriasis can precipitate acute angle-closure glaucoma (usually in those aged over 60 years and hypermetropic (long-sighted), who are predisposed to the condition because of a shallow anterior chamber).</p>
</section>


<section class="tab-pane" id="interactions">
<h2>Interactions</h2>
<h3>For all ANTIMUSCARINICS (SYSTEMIC):</h3>
<hr style="margin: 10px 0;">
<h4>Appendix 1 (antimuscarinics)</h4>
<hr style="margin: 10px 0;">
<p>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation.</p>
<p>Concomitant use of other drugs with antimuscarinic effects can also lead to confusion in the elderly.</p>
<p>List of individual interactants: <a href="#">Atropine</a></p>
</section>



<section class="tab-pane" id="monitoringRequirements">
<h2>Monitoring requirements</h2>
<hr style="margin: 10px 0;">
<section class="patientParameters">
<h4 class="specificity">With <ph outputclass="route">intravenous</ph> use</h4>
<p>Control of muscarinic side-effects of neostigmine in reversal of competitive neuromuscular block</p>
<p>Since atropine has a shorter duration of action than neostigmine, late unopposed bradycardia may result; close monitoring of the patient is necessary.</p>
</section>
</section>

<section class="tab-pane" id="directionsforadministration">
<h2>Directions for administration</h2>
<hr style="margin: 10px 0;">
<section class="generalInformation">
<h4 class="specificity">With oral use in children:</h4>
<ul>
<li>For administration by mouth, injection solution may be given orally.</li>
</ul>
</section>
</section>

<section class="tab-pane" id="unlicensedUse">
<h2>Unlicensed use</h2>
<hr style="margin: 10px 0;">
<h4 class="specificity">When used by <ph outputclass="route">eye</ph> in children</h4>
<ul>
<li>Not licensed for use in children for uveitis.</li>
</ul>
<h4 class="specificity">With <ph outputclass="route">systemic</ph> use in children</h4>
<ul>
<li>Not licensed for use by oral route.</li>
<li>Not licensed for use in children under 12 years for intra-operative bradycardia or by intravenous route for premedication.</li>
<li>Not licensed for the control of muscarinic side-effects of edrophonium in reversal of competitive neuromuscular block.</li>
</ul> 
</section>

<section class="tab-pane" id="prescribingAndDispensingInformation">
<h2>Prescribing and dispensing</h2>
<hr style="margin: 10px 0;">
<section class="prescribingAndDispensingInformation">
<h4 class="specificity">When used by <ph outputclass="route">eye</ph></h4>
<p>Although multi-dose atropine sulphate eye drops commonly contain preservatives, preservative-free unit dose vials may be available.</p>
</section>
</section>



<section class="tab-pane" id="patientandcareradvice">
<h2>Patient and carer advice</h2>
<h3>For all ANTIMUSCARINICS (SYSTEMIC):</h3>
<hr style="margin: 10px 0;">
<h4>Driving and skilled tasks</h4>
<hr style="margin: 10px 0;">
<p>Antimuscarinics can affect the performance of skilled tasks (e.g. driving).</p>
<h3>For all ANTIMUSCARINICS (EYE):</h3>
<hr style="margin: 10px 0;">
<p>Patients may not be able to undertake skilled tasks until vision clears after mydriasis.</p>
</section>

<section class="tab-pane" id="lessSuitableForPrescribing">
<h2>Conditions when less suitable for prescribing</h2>
<hr style="margin: 10px 0;">
            <section class="lessSuitableForPrescribing">
              <h4 class="specificity">With <ph outputclass="route">oral</ph> use in adults</h4>
              <p>Atropine tablets less suitable for prescribing. Any clinical benefit as a gastro-intestinal antispasmodic is outweighed by atropinic side-effects.</p>
            </section>
      </section>




<section class="tab-pane" id="exceptionsToLegalCategory">
<h2>Exceptions to legal category</h2>
<hr style="margin: 10px 0;">
            <section class="exceptionsToLegalCategory">
              <h4 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">subcutaneous</ph> use</h4>
              <p>Prescription only medicine restriction does not apply where administration is for saving life in emergency.</p>
            </section>
      </section>


<section class="tab-pane" id="medicinalForms">
<h2>Medicinal forms</h2>
<hr style="margin: 10px 0;">
<section class="licensingVariationStatement">
<p>There can be variation in the licensing of different medicines containing the same drug.</p>
<p><strong>Forms available from special-order manufacturers include: </strong><br>
eye drops, solution for injection, oral suspension, solution for infusion, oral solution, eye ointment</p>

</section>
        
          
           
<ul class="unstyled">
<li><a href="../medicinalForm/PHP74804.html" data-target="#PHP74804" data-action="load" class="key-link">Tablet</a></li>
<li><a href="../medicinalForm/PHP75143.html" data-target="#PHP75143" data-action="load" class="key-link">Eye drops</a></li>
<li><a href="../medicinalForm/PHP75069.html" data-target="#PHP75069" data-action="load" class="key-link">Solution for injection</a></li>
</ul>
      </section>
    </div>
</div>
<div id="wrap">

 <a href="#top" id="top-link">Back to Top</a>
           

</div>
</div>

<div class="span4">
<h2>Sub-sections</h2>
<ul class="unstyled">
<li><a href="#">Drug interactions: Pirfenidone</a></li>
<li><a href="#">TBC</a></li>
<li><a href="#">TBC</a></li>
</ul>
<h2>Related links</h2>
<ul class="unstyled">
<li><a href="#">TBC</a></li>
<li><a href="#">TBC</a></li>
<li><a href="#">TBC</a></li>
</ul>

</div>
</div>


      
</div></div>        </div>
</div> <!-- layout -->

<div class="callouts">
    <div class="container">
        <a href="/get-involved" class="callout-involved track-link" data-track="getinvolvedtab" data-track-category="get involved tab" data-track-action="clicked" data-track-label="http://www.nice.org.uk/about/nice-communities/local-government">Get involved</a>
    </div>
</div>

<footer class="footer-wrapper">
    <div class="footer">
        <div class="navbar navbar-inverse">
            <div class="navbar-inner">
                <div class="container">
                    <div class="zone zone-footer">

<div class="widget-footer widget-menu-widget widget">
    <div class="widget-content">
      <ul class="nav nav-pills menu">
    
    

<li><a href="/news">News</a>
</li>

<li><a href="/about">About</a>
</li>

<li><a href="/get-involved">Get involved</a>
</li>

<li><a href="/about/nice-communities">Communities</a>
</li>
</ul>
    </div>
  </div>

<div class="widget-footer widget-html-widget widget">
    <div class="widget-content">
      <ul class="nav nav-pills">
<li><a href="/leave-feedback"><span>Leave Feedback</span></a></li>
</ul>
    </div>
  </div></div>
                </div>
            </div>
        </div>
        <div class="container">
            <a href="http://www.nice.org.uk" class="footer-logo"><i class="logo icon-nice-logo"></i></a>

            <ul class="nav nav-services">
                <li><a href="http://pathways.nice.org.uk"><i class="icon-nice-pathways"></i> NICE Pathways</a></li>
                <li><a href="http://www.nice.org.uk/guidance"><i class="icon-nice-guidance"></i> Guidance</a></li>
                <li><a href="http://www.nice.org.uk/standards-and-indicators"><i class="icon-nice-standards"></i> Standards &amp;&nbsp;Indicators</a></li>
                <li><a href="http://www.evidence.nhs.uk"><i class="icon-nice-evidence"></i> Evidence services</a></li>
            </ul>

            <div class="legal-panel">
                <div class="social-panel">
                    <!-- AddThis Button BEGIN -->
                    <p class="social-follow addthis_toolbox">
                        Follow Us
                        <a class="addthis_button_twitter_follow" addthis:userid="nicecomms" target="_blank" title="Follow on Twitter" href="#">
                            <i class="icon-twitter"></i>
                        </a>
                    </p>
                    <!-- AddThis Button END -->
                </div>

                <ul class="nav nav-legal">
                    <li><a href="//www.nice.org.uk/about">About</a></li>
                    <li><a href="//www.nice.org.uk/accessibility">Accessibility</a></li>
                    <li><a href="//www.nice.org.uk/freedom-of-information">Freedom of information</a></li>
                    <li><a href="//www.nice.org.uk/get-involved/contact-us">Contact Us</a></li>
                    <li><a href="//www.nice.org.uk/glossary">Glossary</a></li>
                    <li><a href="//www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li>
                    <li><a href="/news/nice-newsletters-and-alerts">Subscribe</a></li>
                    <li><a href="/help">Help</a></li>
                </ul>

                <p class="legal-copyright">Copyright &copy; 2014 National Institute for Health and Care Excellence. All rights reserved.</p>
            </div>
        </div>
    </div>
</footer>


<script src="//cdn.nice.org.uk/v3/scripts/twitter.bootstrap.min.js" type="text/javascript"></script>
<script src="//cdn.nice.org.uk/v3/scripts/NICE.bootstrap.min.js" type="text/javascript"></script>
<script src="//www.nice.org.uk/Themes/NICE.Bootstrap/scripts/tabdrop/bootstrap-tabdrop.js" type="text/javascript"></script>
<script src="//www.nice.org.uk/Themes/NICE.Bootstrap/scripts/nice/NICE.TabDrop.js" type="text/javascript"></script>
<script src="//s7.addthis.com/js/300/addthis_widget.js#async=1" type="text/javascript"></script>

        

    <script src="//cdn.nice.org.uk/V3/Scripts/nice/NICE.TopHat.dev.js"
            data-environment="Live"
            data-search="/search?q=%term"
            data-typeaheadtype="remote"
            data-typeaheadsource="/autocomplete?%query"
                        async></script>



    
        
        <script type="text/javascript">
            $(document).ajaxSend(function (event, jqxhr, settings) {
                if (settings.url.indexOf("?") >= 0) {
                    settings.url = settings.url + "&ajax=ajax";
                } else {
                    settings.url = settings.url + "?ajax=ajax";
                }
            })
        </script>
        <script type="text/javascript">
            var is_touch_device = 'ontouchstart' in document.documentElement;
            if (is_touch_device) {
                $('body').addClass('touch-screen-device');
            } else {
                $('body').addClass('non-touch-screen-device');
            }
        </script>
    </body>
</html>

